Vejon invites you to join international experts online, discussing new developments in long Covid – symptoms, causes and treatment options. About this event Vejon Long Covid Solutions Congress 2022 This online congress, hosted by Dr Philip McMillan, takes a 360 degree view of long Covid, providing a critical bridge between cutting-edge science and patient therapies.
Dr. McMillan- is there a link to download slide decks for these presentations? That would be terrific. This is a really helpful set of presentations.
Also for Dr. Bruce Patterson's work--I haven't seen anywhere in his papers or recent talks a declaration of financial interest or ownership of the patent for Maraviroc. Can you clarify that Patterson an employee of IncellDX, is himself or his company an owner of the patent for Maraviroc? Shouldn't this be made completely transparent in the presentation disclosures?
I am Registered Nutrition Practitioner. The information shared was very helpful and useful in my clinic. It is not the first time I have clients with MCAS. It is also interesting to note that in my client cohort long covid is common in those with hyperallergic (IgE) profiles.
Dr. McMillan- is there a link to download slide decks for these presentations? That would be terrific. This is a really helpful set of presentations.
Also for Dr. Bruce Patterson's work--I haven't seen anywhere in his papers or recent talks a declaration of financial interest or ownership of the patent for Maraviroc. Can you clarify that Patterson an employee of IncellDX, is himself or his company an owner of the patent for Maraviroc? Shouldn't this be made completely transparent in the presentation disclosures?
https://www.businesswire.com/news/home/20211123005960/en/IncellDx-Awarded-Patent-for-Use-of-CCR5-Antagonist-Maraviroc-in-Treatment-of-COVID-19
I am Registered Nutrition Practitioner. The information shared was very helpful and useful in my clinic. It is not the first time I have clients with MCAS. It is also interesting to note that in my client cohort long covid is common in those with hyperallergic (IgE) profiles.